Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:


Articles on the impact, diagnosis and treatment of the novel coronavirus and COVID-19

Advaccine Acquires Inovio COVID-19 Vaccine in $108 Million Deal

Sinopharm COVID-19 Vaccine is 79% Effective in Phase III Trial

Fosun Forms JV with BioNTech to Manufacture COVID-19 Vaccine

Harbour BioMed Out-Licenses SARS-COV-2 Antibody to AbbVie

Fosun Pharma to Receive 100 Million Doses of COVID-19 Vaccine for China Use

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China